A phase II study of CI-980 in previously untreated extensive small cell lung cancer: An Ohio State University Phase II Research Consortium study

Cancer Investigation

Volumn 20, Issue 2, 2002, Pages 192-198

  Thomas, Jason P ^a   Moore, Timothy ^b   Kraut, Eric H ^a   Balcerzak, Stanley P ^a   Galloway, Sharon ^a   Vandre, Dale D ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b GRANT MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; COLCHICINE; MIVOBULIN ISETHIONATE; TUBULIN; VINCA ALKALOID; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; ELECTROCORTICOGRAPHY; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; LEUKOCYTE; LUNG SMALL CELL CANCER; MALE; METAPHASE; METASTASIS; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBAMATES; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPHILS; PYRAZINES; PYRIDINES;

EID: 0036199652     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120001146     Document Type: Article

References (19)

1. Cancer Statistics, 1998
2. Current therapy of small cell lung cancer
3. Longevity in small cell lung cancer: A report to the lung cancer subcommittee of the United Kingdom coordinating committee for cancer research
4. Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis
5. Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-2-phenylpyrido[3,4-b]pyrazin-7 carbamate 2-hydroxyethanesulfonate hydrate (NSC 370147) against selected tumor cells and in mice
6. Antitumor drug cross resistance in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-78-Yl carbamate 2-hydroxyethanesulfonate hydrate (NSC 370147)
7. A Phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors
8. Phase I and pharmocological study of CI-980, a novel synthetic antimicrotubule agent
9. Toxicity and response criteria of the eastern cooperative oncology group
10. The microtubule skeleton in human phagocytic leukocytes is a very dynamic structure
11. Intensive weekly chemotherapy for the treatment of extensive stage small cell lung cancer
12. Intensive weekly chemotherapy for good-prognosis patients with small cell lung cancer
13. Gemcitabine: A pharmocological and clinical review
14. Topotecan: A review of its efficacy in small cell lung cancer
15. VP-16 and cisplatin as first-line therapy for small cell lung cancer
16. Combination chemotherapy in small cell lung carcinoma: A randomized study of two intensive regimens
17. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity
18. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas
19. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma